Poster Presentations
The Scientific and Organizing Committee thanks all authors for their submissions.
- The posters will be displayed in PRINTED form.
- The poster stand dimensions are w=100 cm, h=200 cm.
- The posters will be displayed during the whole conference in the designated area adjacent to the main lecture hall.
We kindly ask you to set your poster as soon as possible, the stands will be ready on May 16 at 8:00 hrs.
All the abstracts will be published in digital form (pdf file) at the conference website.
The Scientific and Organizing Committee is currently voting for the 5 best abstracts whose authors will be asked to present their poster in a short oral presentation in the main hall (Sat. May 17 at 14:00hrs).
The results will be announced by the end of the week.
Accepted POSTERS
| 1) | Cardiovascular Involvement in Fabry Disease: Association Between Basilar Dolichoectasia and Cardiomyopathy Esteban Calabrese, Guillermo Rodriguez Botta (ARG) |
|---|---|
| 2) | Establishment of a patient-specific endothelial cell model to study immune response and endoplasmic reticulum stress in Fabry disease Elisa Rudolph, Malte Lenders, Eva Brand (DEU) |
| 3) | Identification of new interaction partners and pathways of α-galactosidase A to analyse the pathogenesis of Fabry disease Elise Raphaela Menke, Malte Lenders, Eva Brand (DEU) |
| 4) | Exploring the journey of patients living with Fabry disease in Poland Agnieszka Brzezinska, Anna Moskal, Chris Wingrove, Jayne Gershkowitz, Adrian Goretzki, Bernadeta Prandzioch-Goretzki, Aleksandra Gladys, Michal Nowicki (GBR) |
| 5) | Fabry disease in Argentina: Clinical, biochemical and molecular correlation in all reported GLA variants Juan Politei, Romina Ceci, Domingo Procopio, LUCAS SILVESTROFF, Rita Valdez, Paula Rozenfeld (ARG) |
| 6) | Phase III, Open-label, Switch-over Trial of the Efficacy and Safety of Agalsidase Beta Biosidus (Agalzyme®) in Fabry Disease Patients Previously Stabilized with Fabrazyme® Norberto Antongiovanni, Gustavo Cabrera, Alberto A. Fernández, Norberto Guelbert, Juan M. Muraro, Juan M. Politei, Carlos Cusumano, Fernando Gómez Pizarro, Guillermo Guelbert, Sergio Lucca, Erika Nieto, Fernando Perretta, Nicolás M. Antognoni, Sabrina Coppola, Lucía Giménez, Gabriel D. Robbesaul, Gabino Rolandelli, Hugo Sotelo, Viridiana Berstein (ARG) |
| 7) | Worse pregnancy and delivery outcomes in children with a pathogenic GLA variant - a post-hoc analysis of the PROFABIA study Christopher Paschen, Natalja Haninger‑Vacariu, Constantin Gatterer, Senta Graf, Markus Ponleitner, Paulus Rommer, Raute Sunder-Plassmann, Gere Sunder-Plassmann, Alice Schmidt (AUT) |
| 8) | Maternal and Postnatal Outcomes Study (MOS) in patients with Fabry disease receiving pegunigalsidase alfa – study design Joana Lopes de Almeida , Eleonora Riccio, Benedetta Borella, Giovanni Piotti (ITA) |
| 9) | Exploring genetic factors of Fabry nephropathy progression via whole-exome sequencing Tina Levstek, Bojan Vujkovac, Albina Nowak, João-Paulo Oliveira, Gabriela Dostálová, Aleš Linhart, Markéta Šafaříková, Gheona Altarescu, Katarina Trebušak Podkrajšek (SVN) |
| 10) | Electrocardiographic Features Distinguishing Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy Roberto Giugliani, Fabiano de Oliveira Poswar (BRA) |
| 11) | Preliminary Experience of Switching Agalsidase Beta to Pegunigalsidase Alfa in Six Patients in Finland Jukka Saarinen, Päivi Pietilä-Effati, Susanna Kouhi, Minna Kylmälä, Ilkka Kantola (FIN) |
| 12) | Quality of life of migalastat-treated adolescents with Fabry disease: results from the ASPIRE study and open-label extension Robert J. Hopkin, Amarilis Sanchez-Valle, Esperanza E. Font-Montgomery, Ozlem Goker-Alpan, Damara Ortiz, Chester B. Whitley, William R. Wilcox, Hai Jiang, Lee Ann Lawson, Jennie Vosk, Haichen Yang, Uma Ramaswami (USA) |
| 13) | Clinical assessment of disease severity in patients with Fabry disease treated with pegunigalsidase alfa: an integrated analysis Bojan Vujkovac, Derralynn Hughes, Aleš Linhart, Eric L. Wallace, William R. Wilcox, Chester B. Whitley, Irene Koulinska, Giovanni Piotti, Raul Chertkoff, Sari Alon, Anat Sakov, Antonio Pisani, John A. Bernat (SVN) |
| 14) | Long-term safety and efficacy of migalastat in adolescent patients with Fabry disease: results from the ASPIRE study and open-label extension Uma Ramaswami, Esperanza Font-Montgomery, Ozlem Goker-Alpan, Damara Ortiz, Amarilis Sanchez-Valle, Chester B. Whitley, William R. Wilcox, Hai Jiang, Lee Ann Lawson, Jennie Vosk, Haichen Yang, Robert J. Hopkin (USA) |
| 15) | Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: five-year interim results from the ongoing BRIGHT51 study Antonio Pisani, John A. Bernat, Myrl Holida, Stephen Waldek, William R. Wilcox, Nicola Longo, Ozlem Goker-Alpan, Eric Wallace, Patrick Deegan, Camilla Tøndel, François Eyskens, Ulla Feldt-Rasmussen, Derralynn Hughes, Ankit Mehta, Khan Nedd, David G. Warnock, Giovanni Piotti, Meng Wang, Einat Almon-Brill, Sari Alon, Raul Chertkoff, Ales Linhart (ITA) |
| 16) | Treatment satisfaction in patients with Fabry disease: patient-reported outcomes from the followME Fabry Pathfinders registry and the SATIS-Fab study Ulla Feldt-Rasmussen, Aleš Linhart, Biliana O. Veleva-Rotse, Joseph D. Giuliano, Hai Jiang, Vipul Jain, Caroline Martinez, Olivier Lidove, on behalf of the followME Fabry Pathfinders registry and the SATIS-Fab study investigators (CZE) |
| 17) | Additional value of standard ECG to echo staging in prediction on cardiovascular risk in Anderson Fabry disease Serena Serratore, Maria Alessandra Schiavo, Raffaello Ditaranto, Vanda Parisi, Rosa Lillo, Annamaria Del Franco, Emanuele Monda, Pier Paolo Bocchino, Nevio Taglieri, Claudia Raineri, Chiara Leuzzi, Andrea Barison, Ines Monte, Cinzia Zuchi, Daniele Torella, Francesco Cappelli, Maurizio Pieroni, Francesca Graziani, Iacopo Olivotto, Giuseppe Limongelli, Elena Biagini (ITA) |
| 18) | Evaluating the relationship between infusion-related reactions and antidrug antibody status: results from 109 patients with Fabry disease treated with pegunigalsidase alfa Robert J. Hopkin, Derralynn Hughes, John A. Bernat, Aleš Linhart, Nicola Longo, Camilla Tøndel, Bojan Vujkovac, Antonio Pisani, Jasmine Knoll, Irene Koulinska, Giovanni Piotti, Raul Chertkoff, Sari Alon, Anat Sakov, Eric L. Wallace (USA) |
| 19) | Echocardiographic Analysis: Factors Affecting Mitral Regurgitation in Fabry Disease Alena Vecerova, Gabriela Dostalova, Beata Soltesova, Ales Linhart (CZE) |
| 20) | Uncovering the Fabry Disease treatment experience: a survey of US patients receiving enzyme replacement therapy (ERT) Robert J. Hopkin, Ángel Rosas, Irene Koulinska, Lucas Oliveira (USA) |
| 21) | Real-World Patient Experiences of Enzyme Replacement Therapy (ERT) in Adults with Fabry Disease: A UK Market Research Study Professor Derralynn Hughes, Dr. Gisela Wilcox, Dr. Alison Muir, Dr. Tom Kenny, Dr. Kamran Iqbal, Dr. John Ndikum (GBR) |
| 22) | Novel insights on blood pressure variability impacts on cardiovascular manifestations of Fabry Disease Jan Pudil, Josef Marek, Gabriela Dostalova, Kristyna Bayerova, Beata Soltesova, Ales Linhart (CZE) |
| 23) | The Price of Not Diagnosing Fabry Disease in Puerto Montt, Chile Benjamin Solar, Juan Politei, Felipe Mendez (CHL) |
| 24) | Novel Variant in GLA and Classic Fabry Disease: Defining an Aggressive Phenotype in Southern Chile Benjamin Solar, Juan Politei (CHL) |
| 25) | Trying to Reducing the Burden of Fabry Disease: The Most Southern Chilean Experience Benjamin Solar, Joaquin Cerda, Ivonne Zamorano, Nicole Rivera, Felipe Mendez (CHL) |
